Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04490096 · ClinicalTrials.gov registry record · Phase 1
Multimodal Imaging Outcome Measures for ALS (Image ALS)
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04490096: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT04490096 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04490096, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine whether longitudinal neuroimaging acquired across multiple research and clinical centers is a feasible biomarker to use as an outcome measure for clinical trials in amyotrophic lateral sclerosis (ALS)
Interventions
- DRUG [11C]-PBR28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04490096
The ClinicalTrials.gov registry entry for NCT04490096 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]-PBR28 is the first listed.
NCT04490096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04490096 about?
NCT04490096 is a clinical study titled "Multimodal Imaging Outcome Measures for ALS (Image ALS)". The primary aim of this study is to determine whether longitudinal neuroimaging acquired across multiple research and clinical centers is a feasible biomarker to use as an outcome measure for clinical trials in amyotrophic lateral sclerosis (ALS)
What is the current status of trial NCT04490096?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-02-25. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT04490096?
The interventions under investigation include: [11C]-PBR28 (DRUG).
Who is sponsoring clinical trial NCT04490096?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.